Effective management of oncology patients requires close collaboration between oncologists and cardiologists to monitor, prevent, and treat chemotherapy-induced cardiotoxicity.
May warrant enhanced cardio-oncology collaboration; leaves open optimal monitoring protocols.
High efficacy of contemporary chemical and radiation treatments made it to success in treatment of oncohematological diseases. The fundamentals of many schemes of polychemotherapy of the first line are anthracyclines. Effective treatment of the main disease in many cases is followed by a variety of cardiovascular complications, including severe ones and fatal. It is necessary to consider the possibility not only for development of acute cardiotoxicity, but various complications from cardiovascular system after cessation of antitumor treatment. Algorithm of patients preparing for such treatment must include cardiovascular assessment before the start of drugs, and follow-up during the treatment course. Prevention and treatment of cardiotoxicity are complicated clinical issues due to irreversible and progressing character of most disorders of cardiovascular system. An important issue is a close collaboration of cardiologist and oncologist in patient’s management. It is necessary to have longterm dynamic follow-up of patients after chemotherapy for maximally early diagnostics of cardiovascular complications in long-term period after finishing of antitumor treatment.
No takes yet. Share an insight, caveat, or question.
Гендлин et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: